@inproceedings{inproceedings, title  = {{A randomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGF-TT).}},

 publisher = {{American Society of Clinical Oncology (ASCO)}},

 url = {{}},

 year = {{2014}},

 month = {{5}},

 author = {{Powles T and Oudard S and Escudier BJ and Brown JE and Hawkins RE and Castellano DE and Ravaud A and Staehler MD and Rini BI and Lin W and O'Keeffe B et al}},

 doi = {{10.1200/jco.2014.32.15_suppl.4525}},

 volume = {{32}},

 journal = {{Journal of Clinical Oncology}},

 issue = {{15_suppl}},

 pages = {{4525-4525}},

 note = {{Accessed on 2024/12/21}}}